This paper presents a case study of continuous productivity improvement of an automotive parts production line using Internet of Everything (IoE) data for fault monitoring. Continuous productivity improvement denotes an iterative process of analyzing and updating the production line configuration for productivity improvement based on measured data. Analysis for continuous improvement of a production system requires a set of data (machine uptime, downtime, cycle-time) that are not typically monitored by a conventional fault monitoring system. Although productivity improvement is a critical aspect for a manufacturing site, not many production systems are equipped with a dedicated data recording system towards continuous improvement. In this paper, we study the problem of how to derive the dataset required for continuous improvement from the measurement by a conventional fault monitoring system. In particular, we provide a case study of an automotive parts production line. Based on the data measured by the existing fault monitoring system, we model the production system and derive the dataset required for continuous improvement. Our approach provides the expected amount of improvement to operation managers in a numerical manner to help them make a decision on whether they should modify the line configuration or not.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8587647PMC
http://dx.doi.org/10.3390/s21217366DOI Listing

Publication Analysis

Top Keywords

productivity improvement
20
fault monitoring
20
continuous improvement
16
continuous productivity
12
automotive parts
12
parts production
12
case study
12
monitoring system
12
improvement
10
ioe data
8

Similar Publications

Background: Genetic studies indicate a causal role for microglia, the innate immune cells of the central nervous system (CNS), in Alzheimer's disease (AD). Despite the progress made in identifying genetic risk factors, such as CD33, and underlying molecular changes, there are currently limited treatment options for AD. Based on the immune-inhibitory function of CD33, we hypothesize that inhibition of CD33 activation may reverse microglial suppression and restore their ability to resolve inflammatory processes and mitigate pathogenic amyloid plaques, which may be neuroprotective.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Xuanwu Hospital, Capital Medical University, Beijing, Beijing, China.

Background: Effective early intervention of mild cognitive impairment (MCI) is the key for preventing dementia. However, there is currently no drug for MCI. As a multi-targeted neuroprotective agent, butylphthalide has been demonstrated to repair cognition in patients with vascular cognitive impairment, and has the potential to treat MCI due to Alzheimer's disease (AD).

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW, 2007, NSW, Australia.

Background: Alzheimer's Disease (AD) poses a substantial global health burden, necessitating innovative therapeutic strategies. This study investigates the neuroprotective potential of a chrysin-loaded Nanostructured Lipid Carrier (NLC) drug delivery system in AD management. Employing the high-pressure homogenization method, chrysin-loaded NLCs were meticulously formulated to optimize drug delivery efficiency.

View Article and Find Full Text PDF

Background: Efforts to genetically reverse C9orf72 pathology have been hampered by our incomplete understanding of the regulation of this complex locus.

Method: We generated five different genomic excisions at the C9orf72 locus in a patient-derived iPSC line and a WT line (11 total isogenic lines), and examined gene expression and pathological hallmarks of C9 FTD/ALS in motor neurons differentiated from these lines. Comparing the excisions in these isogenic series removed the confounding effects of different genomic backgrounds and allowed us to probe the effects of specific genomic changes.

View Article and Find Full Text PDF

Background: Alzheimer's disease (AD) is a neurodegenerative disorder without a cure. Targeting this multifactorial disease by repurposing FDA approved drugs serves as a faster mode of treatment due to its pre-established human safety. We tested terazosin (TZ), an a-1 adrenergic receptor (AR) antagonist and phosphoglycerate kinase-1 (PGK1) activator as having potential to treat AD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!